Edition:
United States

Acorda Therapeutics Inc (ACOR.O)

ACOR.O on Nasdaq

25.00USD
23 Feb 2017
Change (% chg)

$-0.25 (-0.99%)
Prev Close
$25.25
Open
$25.25
Day's High
$25.25
Day's Low
$24.50
Volume
517,640
Avg. Vol
682,376
52-wk High
$37.36
52-wk Low
$16.40

ACOR.O

Chart for ACOR.O

About

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. Its commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the... (more)

Overall

Beta: 1.65
Market Cap(Mil.): $1,152.86
Shares Outstanding(Mil.): 46.11
Dividend: --
Yield (%): --

Financials

  ACOR.O Industry Sector
P/E (TTM): -- 44.59 29.71
EPS (TTM): -0.76 -- --
ROI: -3.86 -3.18 12.94
ROE: -5.46 5.86 14.09

BRIEF-Acorda Therapeutics say after Strader's election, board expanded size to 9 directors from 8

* Acorda Therapeutics - after Strader's election to board, board expanded size of board from 8 to 9 directors, number of Class I directors from 2 to 3 Source text: (http://bit.ly/2lHAR03) Further company coverage:

Feb 21 2017

BRIEF-Acorda Therapeutics reports Q4 adj eps of $0.05

* Acorda provides financial and pipeline update for fourth quarter and year end 2016

Feb 14 2017

BRIEF-Acorda Therapeutics Q4 GAAP loss per share $0.07

* Acorda provides financial and pipeline update for fourth quarter and year end 2016

Feb 14 2017

BRIEF-Acorda Therapeutics entered into settlement agreement with Apotex Corp, Apotex Inc on Feb. 8

* Acorda Therapeutics Inc - on Feb 8, 2017, Acorda Therapeutics, inc entered into settlement agreement with Apotex Corporation and Apotex Inc-sec filing

Feb 10 2017

BRIEF-Acorda announces positive phase 3 clinical trial results for CVT-301

* Acorda therapeutics inc - span-pd trial met primary endpoint

Feb 09 2017

BRIEF-Acorda announces 2016 AMPYRA net sales and 2017 financial guidance

* Acorda announces 2016 AMPYRA net sales and 2017 financial guidance at J.P. Morgan healthcare conference

Jan 09 2017

BRIEF-Acorda to discontinue development of Dalfampridine for treatment of post-stroke walking difficulties

* Milestone clinical study did not show sufficient efficacy to support further development of dalfampridine to improve pswd

Nov 21 2016

BRIEF-Acorda Therapeutics Q3 non-GAAP loss per share $0.04

* Acorda provides financial and pipeline update for third quarter 2016

Oct 27 2016

BRIEF-Acorda Therapeutics presents data from clinical and preclinical trials of CVT-301

* Acorda Therapeutics Inc-presents data from clinical and preclinical trials of CVT-301 for treatment of OFF periods in Parkinson's disease

Oct 13 2016

BRIEF-Arbitral Tribunal confirms Acorda's redemption right regarding Biotie shares

* Arbitral Tribunal confirmed Acorda's redemption right regarding Biotie shares

Sep 26 2016

More From Around the Web

Earnings vs. Estimates